Novel Therapeutics
Peptimmune is developing copolymers using the DEEP technology CNS and autoimmune diseases, as well as cancer and other pathologies.
DEEP™ takes advantage of Peptimmune’s know-how in the solid-phase manufacturing of complex peptide mixtures. The technology combines the epitope specificity of a fixed-sequence peptide with the randomness of a broadly immune-interactive copolymer. DEEP is derived from iterative screening, positional scanning peptide libraries, altered peptide ligands, dendrimers/MAPs, and random-sequence copolymers. The DEEP technology can be used to improve the efficacy of fixed epitope/peptide therapies without compromising generalized immune function.
By expanding the epitope of interest using DEEP, copolymers can be generated that have a self-adjuvant-like effect, thus minimizing the importance of extensive formulation development. Depending on the route of administration or formulation, the copolymer may modulate either Th1 or Th2 immunity.
Current Peptide Therapeutic Development
- Inability to always identify immunodominant epitopes
- Peptides unable to induce strong enough immune response
- Tolerance or anaphylaxis
- Need for adjuvants
Peptimmune is developing copolymers using the DEEP technology CNS and autoimmune diseases, as well as cancer and other pathologies.
